Coherus Biosciences Receivables

Coherus Biosciences's receivables stands at $23M as of March 2026. That compares with $60M in the prior-year period — down 62.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Coherus Biosciences reported $23M in receivables versus $60M a year earlier — a 62.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $60M in the prior-year period — down 62.8% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Coherus Biosciences's receivables evolved across reporting periods, while the comparison chart places CHRS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Coherus Biosciences's reading of $23M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.